OBJECTIVE: To evaluate the association between the use of medications potentially containing phthalates and urinary concentrations of specific phthalate metabolites around conception. METHODS: Women enrolled in the Environment and Reproductive Health project from 2006 to 2009 completed questionnaires about the use of medications and provided multiple urine samples before and after conception. We compared the mean urinary concentration of phthalate metabolites between users of phthalate containing medications and a matched unexposed control group. RESULTS: One woman used Asacol(®) (mesalamine), which utilizes dibutyl phthalate (DBP) as a delayed release coating material, and had a mean urinary concentration of the main DBP metabolite 200 times higher than the controls (8176μg/L vs. 37.5μg/L). The three users of stool softeners had a higher concentration of the main diethyl phthalate (DEP) metabolite (8636μg/L vs. 714.2μg/L). Neither the three additional Prilosec(®) (omeprazole) users nor one cyclobenzaprine user had higher urinary concentration than controls. CONCLUSION: Selected medications may be important sources of DBP and DEP exposures around conception.
OBJECTIVE: To evaluate the association between the use of medications potentially containing phthalates and urinary concentrations of specific phthalate metabolites around conception. METHODS:Women enrolled in the Environment and Reproductive Health project from 2006 to 2009 completed questionnaires about the use of medications and provided multiple urine samples before and after conception. We compared the mean urinary concentration of phthalate metabolites between users of phthalate containing medications and a matched unexposed control group. RESULTS: One woman used Asacol(®) (mesalamine), which utilizes dibutyl phthalate (DBP) as a delayed release coating material, and had a mean urinary concentration of the main DBP metabolite 200 times higher than the controls (8176μg/L vs. 37.5μg/L). The three users of stool softeners had a higher concentration of the main diethyl phthalate (DEP) metabolite (8636μg/L vs. 714.2μg/L). Neither the three additional Prilosec(®) (omeprazole) users nor one cyclobenzaprine user had higher urinary concentration than controls. CONCLUSION: Selected medications may be important sources of DBP and DEP exposures around conception.
Authors: L G Parks; J S Ostby; C R Lambright; B D Abbott; G R Klinefelter; N J Barlow; L E Gray Journal: Toxicol Sci Date: 2000-12 Impact factor: 4.849
Authors: Antonia M Calafat; Manori J Silva; John A Reidy; L Earl Gray; Ella Samandar; James L Preau; Arnetra R Herbert; Larry L Needham Journal: J Toxicol Environ Health A Date: 2006-02
Authors: A K Hotchkiss; L G Parks-Saldutti; J S Ostby; C Lambright; J Furr; J G Vandenbergh; L E Gray Journal: Biol Reprod Date: 2004-07-30 Impact factor: 4.285
Authors: Thuy T B Vo; Eui-Man Jung; Vu Hoang Dang; Yeong-Min Yoo; Kyung-Chul Choi; Frank H Yu; Eui-Bae Jeung Journal: Reprod Biol Endocrinol Date: 2009-09-26 Impact factor: 5.211
Authors: Dana B Barr; Manori J Silva; Kayoko Kato; John A Reidy; Nicole A Malek; Donald Hurtz; Melissa Sadowski; Larry L Needham; Antonia M Calafat Journal: Environ Health Perspect Date: 2003-07 Impact factor: 9.031
Authors: Shanna H Swan; Katharina M Main; Fan Liu; Sara L Stewart; Robin L Kruse; Antonia M Calafat; Catherine S Mao; J Bruce Redmon; Christine L Ternand; Shannon Sullivan; J Lynn Teague Journal: Environ Health Perspect Date: 2005-08 Impact factor: 9.031
Authors: Laura E Dodge; Katherine E Kelley; Paige L Williams; Michelle A Williams; Sonia Hernández-Díaz; Stacey A Missmer; Russ Hauser Journal: Reprod Toxicol Date: 2015-02-26 Impact factor: 3.143
Authors: Laura E Dodge; Jee Woong Choi; Katherine E Kelley; Sonia Herńandez-D Iaz; Russ Hauser Journal: Environ Res Date: 2018-04-03 Impact factor: 6.498